Saturday 17 October 2026
Export VAXX’s income statement to Excel — free account
Vaxxinity, Inc.
VAXX Healthcare Biotechnology
0.00
0.00
NaN
Follow VAXX
Vaxxinity, Inc. (VAXX) EV/Sales
As of 16 October 2026, Vaxxinity, Inc. (VAXX) trades at a EV/Sales of −94.2×. Over the past ten years it has ranged from −94.2× (October 2026) to 4,148× (April 2022) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2021 | 1,612× | (4.99%) |
| FY2020 | 1,696× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2021 | 1,612× | (4.99%) |
| Sep 2021 | 1,696× | 0.00% |
| Mar 2021 | 1,696× | 0.00% |
| Sep 2020 | 1,696× | 0.00% |
| 1 more quarters | Free account |
Against its own ten years
Low −94.2×
High 4,148×
Ten-year median
120×
Current reading's percentile
31
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VAXX Vaxxinity, Inc. | −94.2× |
| TCRX TScan Therapeutics, Inc. compare | −5.3× |
| AKTX Akari Therapeutics PLC compare | n/m |
| NCEL NewcelX Ltd. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | 0.1× |
| MRKR MARKER THERAPEUTICS, INC. compare | 1.9× |
| DARE Dare Bioscience, Inc. compare | 4.7× |
| GTBP GT Biopharma, Inc. compare | 543× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)